Anti-Hu CD243 Purified

Anti-Hu CD243 Purified
Regulatory status
RUO
Antigen
CD243
Clone
UIC2
Format
Purified
Reactivity
Human
Application
IP, FC (QC tested), IHC(F), IHC(P)
Variant
0.1 mg
11-764-C100
In stock

0.025 mg
11-764-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG2a kappa
Specificity
The mouse monoclonal antibody UIC2 recognizes an extracellular epitope on CD243 (MDR-1), an approximately 170 kDa ABC transporter expressed on hematopoietic stem cells, B, T, and NK cells, or on many multidrug resistant cancer cells. This antibody preferentially recognizes CD243 in the process of transporting substrate.
Workshop
HLDA VII
Application
IP, FC (QC tested), IHC(F), IHC(P)
Reactivity
Human
Negative species
Mouse, Rat
Immunogen
NIH 3T3 cells transfected with human CD243 (MDR-1) cDNA
Other names
P-Glycoprotein, CLCS, MDR1, PGY1, ABC20, GP170, ABCB1, ABC transporter
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Kelley DJ, Pavelic ZP, Gapany M, Stambrook P, Pavelic L, Gapany S, Gluckman JL: Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):411-4.
PubMed
Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM: Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm. 2010 Jun 7;7(3):642-51.
PubMed
Goda K, Fenyvesi F, Bacsó Z, Nagy H, Márián T, Megyeri A, Krasznai Z, Juhász I, Vecsernyés M, Szabó G Jr: Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ther. 2007 Jan;320(1):81-8.
PubMed
Mechetner EB, Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5824-8.
PubMed
Chaudhary PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992 Dec 1;80(11):2735-9.
PubMed
Variant
0.1 mg
11-764-C100
In stock

0.025 mg
11-764-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock